61735-56-6

Usage

Uses

Used in Pharmaceutical Industry:
5-Iodonaphthalen-1-ol is used as a building block for the synthesis of various organic compounds, particularly in the development of pharmaceuticals. Its unique structure allows for the creation of new drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Iodonaphthalen-1-ol serves as a key intermediate in the synthesis of compounds with pesticidal properties, contributing to the development of effective and environmentally friendly crop protection agents.
Used in Organic Chemistry:
5-Iodonaphthalen-1-ol is utilized as a reagent in various organic chemistry reactions, facilitating the synthesis of complex organic molecules and aiding in the advancement of chemical research.
Used in Dyes and Pigments Production:
Due to its unique structure, 5-Iodonaphthalen-1-ol is used as an intermediate in the production of dyes and pigments, contributing to the development of new colorants with improved properties for various applications.
Used in Materials Science and Nanotechnology:
5-Iodonaphthalen-1-ol has potential applications in the field of materials science and nanotechnology, where its interesting chemical properties and reactivity can be harnessed to develop new materials with unique properties and functions.

Upstream product

• 83-55-6 5-amino-1-naphthol 

Downstream Products

• 61735-51-1 1-iodo-5-methoxynaphthalene 
• 923275-94-9 1-(2-(2-(2,6-diisopropylphenoxy)ethoxy)ethoxy)-5-iodonaphthalene 
• 923275-96-1 1-(2-(2-(2,6-diisopropylphenoxy)ethoxy)ethoxy)-5-ethynylnaphthalene 
• 923275-95-0 ((5-(2-(2-(2,6-diisopropylphenoxy)ethoxy)ethoxy)naphthalenyl)ethynyl)trimethylsilane 
• 923275-87-0 1,4-bis(5-(2-(2-(2,6-diisopropylphenoxy)ethoxy)ethoxy)naphthalene-1-yl)buta-1,3-diyne 
• 923275-85-8 5-[4-(5-{2-[2-(2,6-diisopropyl-phenoxy)-ethoxy]-ethoxy}-naphthalen-1-ylethynyl)-phenyl]-2-{4-[2-(2-{4-[tris-(4-tert-butyl-phenyl)-methyl]-phenoxy}-ethoxy)-ethylsulfanyl]-[1,3]dithiol-2-ylidene}-5H-[1,3]dithiolo[4,5-c]pyrrole 
• 2437-16-3 5-hydroxy-1-naphthoic acid 
• 51934-37-3 5-methoxy-1-naphthoic acid 
• 91307-40-3 methyl 5-hydroxy-1-naphthoate 

Relevant academic research and scientific papers

Mixed-Valent Molecular Triple Deckers

Two phenothiazine (PTZ) moieties were connected via naphthalene spacers to a central arene to result in stacked PTZ-arene-PTZ structure elements. Benzene and tetramethoxybenzene units served as central arenes mediating electronic communication between the two PTZ units. Based on cyclic voltammetry, UV/Vis-NIR absorption, EPR spectroscopy, and computational studies, the one-electron oxidized forms of the resulting compounds behave as class II organic mixed-valence species in which the unpaired electron is partially delocalized over both PTZ units. The barrier for intramolecular electron transfer depends on the nature of the central arene sandwiched between the two PTZ moieties. These are the first examples of rigid organic mixed-valent triple-decker compounds with possible electron-transfer pathways directly across a stacked structure, and they illustrate the potential of oligo-naphthalene building blocks for long-range electron transfer and a future molecular electronics technology.

COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS

Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX)

Functionally rigid bistable [2]rotaxanes

Two-station [2]rotaxanes in the shape of a degenerate naphthalene (NP) shuttle and a nondegenerate monopyrrolotetrathiafulvalene (MPTTF)/NP redox-controllable switch have been synthesized and characterized in solution. Their dumbbell-shaped components are

Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors

A series of novel 8-substituted dipyridodiazepinone-based inhibitors were investigated for their antiviral activity against wild type human immunodeficiency virus (HIV-1) and the clinically prevalent K103N/Y181C mutant virus. Our efforts have resulted in a series of benzoic acid analogues that are potent inhibitors of HIV-1 replication against a panel of HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Furthermore, the combination of good antiviral potency, a broad spectrum of activity, and an excellent pharmacokinetic profile provides strong justification for the further development of compound 7 as a potential treatment for wild type and NNRT1-resistant HIV-1 infection.